Winners and losers: who had a good week — and who didn't

Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown — of individuals, companies, what have you — that accomplished

something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out,

even the losers. WINNERS: NOVO NORDISK scored a modest publicity coup by very publicly committing to limiting price hikes on its medicines to single-digit increases annually. The company is

now the second big drug maker to do so, after Allergan. And while many people may not have read his note, Novo president Jakob Riis carefully and calmly used the opportunity to skewer

pharmacy benefit managers and insurers, which the pharmaceutical industry is increasingly blaming for the rising cost of medicines. DR. SCOTT GOTTLIEB makes our list since he appears to be a

strong candidate for Food and Drug Administration commissioner. He was once a deputy commissioner at the agency, and is now a policy wonk, consultant to drug makers, and pharma company

board member. But his biggest attribute may simply be that he is not Jim O’Neill, another name in the ring who once suggested drugs should be approved without evidence of being effective, an

idea that is being widely ridiculed in many circles. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH

ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+.

Subscribe